Sermorelin is one of the older peptides in the growth hormone conversation, and one of the better-studied, though interestingly, mostly in children. Kiral offers it for adults. Before you decide whether it fits your goals, here is what the published literature supports and what it doesn’t.
The short version
Sermorelin has solid human data for diagnosing and treating growth hormone deficiency (GHD) in children. It has much thinner evidence for the uses most adults ask about today. The robust efficacy evidence is confined to pediatric idiopathic GHD and diagnostic testing. Popular current uses, including body-fat reduction, connective-tissue healing, anti-aging, and athletic performance, are not supported by efficacy data showing clinically meaningful changes in body composition in healthy adults [2].
What is sermorelin?
Sermorelin is a synthetic 29-amino-acid analogue of the N-terminal fragment (1-29) of growth hormone-releasing hormone (GHRH). It is the shortest peptide that retains the full biological activity of GHRH [1]. It prompts the pituitary to release growth hormone (GH) in its natural, pulsatile pattern and raises serum IGF-1, while keeping the body’s negative-feedback control of the GH/IGF-1 axis intact. That is a mechanistic contrast with injected recombinant hGH [2,1].
The FDA approved sermorelin (as Geref) for pediatric GH deficiency. The manufacturer withdrew it in 2008 for commercial reasons, not safety reasons, so it remains legally prescribable and compoundable [2].
Human data in children
Diagnostic use. Sermorelin was best validated as a provocative test for GH deficiency. A single IV dose of 1 µg/kg produces a rapid, relatively GH-specific response, with fewer false positives in children who are not deficient than other provocative tests [1].
The main limitation is that a normal response to IV sermorelin cannot rule out GH deficiency of hypothalamic origin. A subnormal response to a conventional provocative test is still needed to confirm disease in those patients. Combining IV sermorelin with arginine improves specificity [1].
Treatment. Once-daily subcutaneous sermorelin at 30 µg/kg at bedtime produced significant, sustained increases in height velocity over 12 months. Most GH-deficient children showed catch-up growth, and some data suggest the effect held to 36 months. Responders tended to be slow-growing, shorter children with delayed bone and height age [1].
Sermorelin was less effective than somatropin. Height-velocity gains at 30 µg/kg/day were smaller than with once-daily subcutaneous somatropin at the same dose, and effects on final adult height were never established [1].
Human data in adults and aging
The adult data are modest and mixed:
- Six weeks of treatment
In adults treated with sermorelin for 6 weeks, nocturnal GH release and peak amplitude increased. Body weight, BMI, waist-to-hip ratio, and body composition did not change [2]. - A related analogue, over five months
A 5-month course of a closely related analogue, [Nle27]GHRH(1-29)NH₂, increased lean body mass by 2.3% in men, with no change in fat mass [2]. - Cognition in older adults
A 6-month course of sermorelin acetate reportedly improved cognitive function in healthy adults aged 60 to 85 [4].
Raising GH release is not the same as producing a meaningful change in how people look, feel, or perform.
The adult studies so far show the first more clearly than the second.
Preclinical and pharmacokinetic data
Short half-life. Sermorelin’s main pharmaceutical limitation is a plasma half-life of roughly 10 to 20 minutes in humans, driven by renal ultrafiltration and enzymatic degradation at the N-terminus [5].
PEGylation. Much of the preclinical work has aimed at extending that half-life. In rat and pig models, mono-PEGylated versions of GRF(1-29) (PEG5000 at Lys12 or Lys21) kept high in vitro bioactivity and produced a greater GH response than the unmodified peptide. This stabilization strategy ultimately informed the development of tesamorelin, a longer-acting, FDA-approved GHRH analogue [5,6].
Other research areas. Transcriptomic and drug-screening data suggest recurrent glioma may be more sensitive to sermorelin, with potential tumor-growth inhibition and immune enhancement. This remains experimental. Broader GHRH-analogue research spans cardiology, oncology, metabolic, inflammatory, and neurodegenerative applications [4].
Safety
Across pediatric and adult studies, single IV doses and repeated daily subcutaneous dosing were well tolerated. The most common adverse effects were transient facial flushing and injection-site pain. Headache, dizziness, and hypoglycemia were also reported [1,2].
There is a practical caveat as well. Because sermorelin is now largely obtained through compounding, preparations that are not made to GMP standards carry risks of contamination, inaccurate identity or concentration, and degradation products [2]. Where and how a peptide is sourced matters as much as the peptide itself.
Where Kiral fits in
We offer sermorelin at Kiral, and we want to be up front about what that means. The evidence behind it is strongest in children with a diagnosed GH deficiency. For the adult goals people often bring to us, the data are limited, and we won’t tell you otherwise.
That gap is why we think real-world data matter. By carefully tracking outcomes and safety in the people we care for, we aim to add to the body of literature. This doesn’t replace controlled trials, but it gives researchers and clinicians more to work with than a handful of short adult studies. If you’re considering sermorelin, talk with your Kiral clinician about whether it makes sense for you, what to realistically expect, and how we’ll monitor your response.
References
1. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157. doi:10.2165/00063030-199912020-00007
2. Mendias CL, Awan TM. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Med. 2026;56(8):1921-1935. doi:10.1007/s40279-026-02437-0
3. Mendias CL, Awan TM. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Med. 2026;56(8):1921-1935. doi:10.1007/s40279-026-02437-0
4. Granata R, Leone S, Zhang X, et al. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025;21(3):180-195. doi:10.1038/s41574-024-01052-1
5. Esposito P, Barbero L, Caccia P, et al. PEGylation of growth hormone-releasing hormone (GRF) analogues. Adv Drug Deliv Rev. 2003;55(10):1279-1291. doi:10.1016/s0169-409x(03)00109-1
6. Montero-Hidalgo AJ, Del Rio-Moreno M, Pérez-Gómez JM, Luque RM, Kineman RD. Update on regulation of GHRH and its actions on GH secretion in health and disease. Rev Endocr Metab Disord. 2025;26(3):305-320. doi:10.1007/s11154-025-09943-y
7. Granata R, Leone S, Zhang X, et al. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025;21(3):180-195. doi:10.1038/s41574-024-01052-1
This post is for educational purposes and isn’t medical advice. Talk with a qualified clinician before starting any peptide therapy.